Share on StockTwits

Tekmira Pharmaceuticals (NASDAQ:TKMR) was the target of a significant growth in short interest in April. As of April 30th, there was short interest totalling 1,139,337 shares, a growth of 29.6% from the April 15th total of 879,324 shares, AnalystRatingsNetwork.com reports. Approximately 6.6% of the company’s stock are short sold. Based on an average daily trading volume, of 566,050 shares, the days-to-cover ratio is currently 2.0 days.

TKMR has been the subject of a number of recent research reports. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Tekmira Pharmaceuticals in a research note on Thursday, May 15th. They now have a $31.00 price target on the stock, down previously from $37.00. Separately, analysts at TheStreet downgraded shares of Tekmira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, April 11th. Finally, analysts at RBC Capital initiated coverage on shares of Tekmira Pharmaceuticals in a research note on Friday, April 11th. They set an “outperform” rating and a $30.00 price target on the stock.

Tekmira Pharmaceuticals (NASDAQ:TKMR) opened at 11.78 on Tuesday. Tekmira Pharmaceuticals has a 52-week low of $4.61 and a 52-week high of $31.48. The stock has a 50-day moving average of $15.33 and a 200-day moving average of $14.24.

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (NASDAQ:TKMR) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.